Digital health platform, B2B white-label solution, exclusive technology license

The software platform processes blood test data and lifestyle information and converts it into structured, easy-to-understand wellness reports for end users. The results can be integrated into existing offerings by laboratory and testing providers, preventive care clinics, and digital health platforms as a white-label component. The focus is on non-clinical, preventive use with technology-supported, user-friendly presentation of complex laboratory information.

The company does not sell directly to end consumers, but rather to business partners who already have access to health-conscious end users. These partners integrate the analysis as a white-label component into their own offerings and present it to their customers under their own brand.

The focus is on three customer segments:

Laboratory and testing providers. Providers of blood tests and laboratory services who currently supply their customers with raw test results but are unable to provide an easy-to-understand interpretation. For them, the platform offers a way to increase the value per test without having to develop their own software. This segment generates the highest volumes per partner.

Preventive care providers and digital health platforms. Preventive care clinics, longevity and check-up providers, as well as app-based health platforms that want to expand their offerings to include a data-driven interpretation layer. This segment makes decisions quickly; accordingly, this is where the platform’s initial customers have come from.

Insurers and workplace health programs. Health and supplemental insurance providers, as well as employers with health promotion budgets. Longest decision-making cycle, but with the largest volumes and long contract terms. This segment is in the early stages but has not yet contributed to revenue.

A common characteristic of all customers: They already have customer access and the data source; what they lack is the interpretation and visualization layer. Sales are not driven by marketing budgets but rather through integration into existing processes. This leads to long lead times but high customer retention after the contract is signed, as switching analytics providers would require the partner to incur the cost of re-integration.

Geographically, the focus is currently on German-speaking countries, with initial discussions underway in other European markets. Due to the early stage of the business, the customer base is still small and correspondingly concentrated.

The company operates in the growing market for digital preventive healthcare, personalized health information, and data-driven wellness applications. The market is driven by rising health awareness, an increasing demand for individualized preventive services, and the ongoing digitization of laboratory, healthcare, and preventive services. For laboratory providers, preventive care clinics, and digital health platforms, the integration of easy-to-understand analysis and supplementary services into existing offerings is becoming increasingly important. The company benefits from the growing demand for scalable white-label solutions and a patent-protected technology base with additional development potential.

The competitive landscape can be divided into four groups.

First, D2C providers of blood tests that perform their own analysis. Internationally funded providers that offer testing, analysis, and end-customer relationships all under one roof. They are well-capitalized and have strong brands, but they compete directly with the partners the company serves. For a laboratory or preventive care provider, they are therefore not a potential supplier but a competitor. The company deliberately avoids competing against its own customers, which is what makes it compatible with this group in the first place.

Second, laboratory information systems and results portals. Established providers with high market penetration in the laboratory sector. Their strength lies in process management and the transmission of test results, not in interpretation. They are integration partners rather than competitors, but could establish their own interpretation capabilities in the medium term.

Third, in-house development by the customer. In practice, this is the most common competitor. Larger partners regularly consider building their own analysis capabilities. This usually fails due to a lack of scientific foundation, the challenge of maintaining reference logic over time, and a lack of rights to validated methodology. This is precisely where the company’s advantage lies.

Fourth, generic wellbeing and longevity apps. Large in number, shallow in scientific depth, and with little integration capability. They capture attention but do not occupy the B2B interface.

The company’s competitive advantage:

Exclusivity. The underlying technology is exclusively licensed from a publicly funded European research institution. A competitor cannot easily replicate or license the same foundation. This is the strongest part of the moat.

Business model over brand. The company remains invisible behind the partner’s brand. It thus avoids investing in expensive end-customer acquisition, an area where well-capitalized D2C providers would have a structural advantage.

Switching costs. Once integrated into a partner’s processes, switching providers involves additional technical and, later, regulatory effort. This creates loyalty that extends beyond the individual contract.

Two-tier regulatory approach. The current offering is deliberately positioned as non-clinical and can therefore be used without an approval process. The license also includes the rights for future regulated medical use. Competitors usually have to choose between one of these two approaches.

Realistic assessment: The biggest challenge is not technological differentiation, but capital and distribution reach. Several competitors are significantly better funded. An acquirer with existing market access can close precisely this gap; this is a key part of the rationale behind the transaction.